Nobody expected stellar first-quarter results from Eli Lilly, which is this year in the thick of its sales decline. That said, the Indianapolis-based drugmaker hit the profits numbers analysts did expect, with a soon-to-be-expanded animal health division holding the company's sales dip to just below Wall Street's predictions.
written on 24.04.2014